Antivirals
|
|
Your reliable supplier of generic medications.
|
|
|
Hi.
just want to say thanks for your promt and efficient service.. The tablets arrived well within the timeframe given.. Have passed on your
address, dont know wheather its been used or not..
Best regards... and happy St Patricks from the Irish in France..
- Kieran
Our billing is certified by:
- What’s best at beating swine flu, soap or gel?
Commuters obsessively scrub their hands with gel.
- Swine flu drug treatment will replace containment strategy
More than 150 people have been diagnosed with swine flu over the past 24 hours as the rate of infection accelerates, pushing the total number of UK cases above 1,000.
- Is the flu jab a waste of time?
On balance, probably not.
- Global flu pandemic would probably kill 62m, study says
Around 62 million people in the world are likely to die if there is a flu pandemic and more than 70,000 of those deaths will be in the UK, according to a statistical analysis published today.
- Vaccine against lethal strain of avian flu ready for human testing
A British drug company is seeking permission to conduct the first human trials of an experimental vaccine against the avian flu virus.
- Broad-Spectrum Antivirals: The Future of HIV Treatment? - TheBody.com
Broad-Spectrum Antivirals: The Future of HIV Treatment?TheBody.
- The Global Antivirals Market Expected To Reach $30 Billion By 2017 - OfficialWire (press release)
The Global Antivirals Market Expected To Reach $30 Billion By 2017OfficialWire (press release)by Press Office In 2010, the global antivirals market was estimated to be worth $22.
- deadly pandemic a matter of when, not if - Sydney Morning Herald
deadly pandemic a matter of when, not ifSydney Morning HeraldThe drugs that would help are the antivirals, such as Relenza and Tamiflu.
- New Antivirals Show Poor Safety in HCV With Cirrhosis - Medscape
New Antivirals Show Poor Safety in HCV With CirrhosisMedscapeMay 2, 2012 (Barcelona, Spain) — Two relatively new direct-acting antiviral drugs have poor safety profiles in patients with hepatitis C virus (HCV) and cirrhosis, including a high rate of serious adverse events leading to study discontinuation.
- Experts Discuss DAAs for Difficult-To-Treat Hep C Patients - Infectious Disease Special Edition
Infectious Disease Special EditionExperts Discuss DAAs for Difficult-To-Treat Hep C PatientsInfectious Disease Special Editionby Christina Frangou San Francisco—For several months, it has been one of the most pressing questions among clinicians who treat patients with hepatitis C: How well do the two FDA-approved direct-acting antivirals (DAAs) perform in the patients who .
 |
Bookmark this site |
|---|
 |
Subscribe to the News |
|---|
Canada Pharmacy
Canadian Pharmacy
